Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313404837> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313404837 endingPage "54.20" @default.
- W4313404837 startingPage "54.20" @default.
- W4313404837 abstract "Abstract Irradiation damages both proteins and DNA, which reduces the cytotoxicity of NK-92 cells as well as preventing their growth and engraftment when used for adoptive immunotherapies of cancer. We evaluated the DNA topoisomerase inhibitor irinotecan (CPT-11) as an alternative method to 10 Gy irradiation that might better preserve the perforin-granzyme cytotoxicity mediated by NK-92 cells towards tumor cells. Irinotecan is enzymatically converted into an active metabolite SN-38 which promotes its potential to become a delayed inhibitor in comparison to camptothecin which is a structurally similar topoisomerase inhibitor that is immediately active. We pretreated NK-92 cells for 4 hours with different concentrations of CPT-11, and measured NK-92 cell death and the effects on cell-mediated cytotoxicity towards Raji tumor cells (measured by 51Cr release one day after pretreatment). Previous experiments with 10 Gy irradiation were used for comparative purposes. Irinotecan had a dose response on cell death which progressed for 5 days. We found that one day after pretreatment with as little as 80 – 100 uM CPT-11, viable cell recoveries were similar to 10 Gy irradiated with over 50% compared to the counts of control cells. Activity of the viable cells after CPT-11 pretreatment, compared by lytic units, was over 30% conserved whereas irradiated cell activity was 2.9%, compared to controls. This data demonstrate that the negative effects of anti-proliferative treatment are less pronounced with irinotecan, than for irradiation. We conclude that optimization of dosage and exposure times to irinotecan may offer a means to prolong the life and function of NK-92 cells that are used for adoptive immunotherapies. Supported by the Nevada INBRE NIH GM103440, for student summer research scholarship and the UNR Foundation C.E. Hudig Fund." @default.
- W4313404837 created "2023-01-06" @default.
- W4313404837 creator A5001333899 @default.
- W4313404837 creator A5041198153 @default.
- W4313404837 creator A5042879572 @default.
- W4313404837 creator A5045238874 @default.
- W4313404837 creator A5084120850 @default.
- W4313404837 creator A5088904153 @default.
- W4313404837 date "2022-05-01" @default.
- W4313404837 modified "2023-10-16" @default.
- W4313404837 title "Evaluation of the DNA topoisomerase inhibitor irinotecan (CPT-11) as an alternative to irradiation for pretreatment of NK-92s prior to adoptive cell immunotherapy." @default.
- W4313404837 doi "https://doi.org/10.4049/jimmunol.208.supp.54.20" @default.
- W4313404837 hasPublicationYear "2022" @default.
- W4313404837 type Work @default.
- W4313404837 citedByCount "0" @default.
- W4313404837 crossrefType "journal-article" @default.
- W4313404837 hasAuthorship W4313404837A5001333899 @default.
- W4313404837 hasAuthorship W4313404837A5041198153 @default.
- W4313404837 hasAuthorship W4313404837A5042879572 @default.
- W4313404837 hasAuthorship W4313404837A5045238874 @default.
- W4313404837 hasAuthorship W4313404837A5084120850 @default.
- W4313404837 hasAuthorship W4313404837A5088904153 @default.
- W4313404837 hasConcept C109316439 @default.
- W4313404837 hasConcept C121608353 @default.
- W4313404837 hasConcept C147897179 @default.
- W4313404837 hasConcept C185592680 @default.
- W4313404837 hasConcept C202751555 @default.
- W4313404837 hasConcept C203014093 @default.
- W4313404837 hasConcept C2776062744 @default.
- W4313404837 hasConcept C2778616834 @default.
- W4313404837 hasConcept C2779682216 @default.
- W4313404837 hasConcept C2780259306 @default.
- W4313404837 hasConcept C502942594 @default.
- W4313404837 hasConcept C526805850 @default.
- W4313404837 hasConcept C54355233 @default.
- W4313404837 hasConcept C552990157 @default.
- W4313404837 hasConcept C55493867 @default.
- W4313404837 hasConcept C86803240 @default.
- W4313404837 hasConcept C98274493 @default.
- W4313404837 hasConceptScore W4313404837C109316439 @default.
- W4313404837 hasConceptScore W4313404837C121608353 @default.
- W4313404837 hasConceptScore W4313404837C147897179 @default.
- W4313404837 hasConceptScore W4313404837C185592680 @default.
- W4313404837 hasConceptScore W4313404837C202751555 @default.
- W4313404837 hasConceptScore W4313404837C203014093 @default.
- W4313404837 hasConceptScore W4313404837C2776062744 @default.
- W4313404837 hasConceptScore W4313404837C2778616834 @default.
- W4313404837 hasConceptScore W4313404837C2779682216 @default.
- W4313404837 hasConceptScore W4313404837C2780259306 @default.
- W4313404837 hasConceptScore W4313404837C502942594 @default.
- W4313404837 hasConceptScore W4313404837C526805850 @default.
- W4313404837 hasConceptScore W4313404837C54355233 @default.
- W4313404837 hasConceptScore W4313404837C552990157 @default.
- W4313404837 hasConceptScore W4313404837C55493867 @default.
- W4313404837 hasConceptScore W4313404837C86803240 @default.
- W4313404837 hasConceptScore W4313404837C98274493 @default.
- W4313404837 hasIssue "1_Supplement" @default.
- W4313404837 hasLocation W43134048371 @default.
- W4313404837 hasOpenAccess W4313404837 @default.
- W4313404837 hasPrimaryLocation W43134048371 @default.
- W4313404837 hasRelatedWork W1620348927 @default.
- W4313404837 hasRelatedWork W1988529521 @default.
- W4313404837 hasRelatedWork W1995556774 @default.
- W4313404837 hasRelatedWork W2021660653 @default.
- W4313404837 hasRelatedWork W2054837357 @default.
- W4313404837 hasRelatedWork W2155243531 @default.
- W4313404837 hasRelatedWork W2387309107 @default.
- W4313404837 hasRelatedWork W2400845519 @default.
- W4313404837 hasRelatedWork W2409264349 @default.
- W4313404837 hasRelatedWork W4313404837 @default.
- W4313404837 hasVolume "208" @default.
- W4313404837 isParatext "false" @default.
- W4313404837 isRetracted "false" @default.
- W4313404837 workType "article" @default.